Bioxyne Gets Green Light for Medical Cannabis Manufacturing

Bioxyne’s subsidiary, Breathe Life Sciences, has secured a GMP license from the TGA to manufacture medical cannabis products in Australia.

Bioxyne’s subsidiary, Breathe Life Sciences, has secured a good manufacturing practice (GMP) license from the Therapeutic Goods Administration (TGA) to manufacture medical cannabis products in Australia. The license covers the production of active pharmaceutical ingredients (APIs) for MDMA, psilocybin, and cannabis, as well as the preparation of final doses in capsule form for clinical trials and prescribers.

The GMP license is a significant milestone for Bioxyne, as it enables the company to enter the rapidly growing medical cannabis market in Australia and abroad. The company plans to register its products on the Australian Register of Therapeutic Goods for export in 2024, and to supply universities, clinical trials, and companies worldwide with its medical cannabis products.

Bioxyne’s medical cannabis products are based on its proprietary brand, Dr Watson, which offers a range of CBD and THC products for various health conditions and wellness purposes. The company’s products are formulated with natural ingredients and backed by scientific research and clinical evidence.

Bioxyne is committed to the responsible and ethical manufacture of alternative medicines, and aims to provide solutions for mental health disorders

Bioxyne is committed to the responsible and ethical manufacture of alternative medicines, and aims to provide solutions for mental health disorders that are resistant to current treatments. The company is focused on developing and delivering MDMA and psilocybin products for the treatment of post-traumatic stress disorder (PTSD), depression, anxiety, and addiction.

Bioxyne is also dedicated to ensuring social equity and justice in the medical cannabis industry, by providing more opportunities and support for women, minorities, and small businesses to enter the market. The company also intends to expunge and seal the criminal records of people who have been convicted of low-level cannabis offenses in the past, and to provide them with access to education, training, and employment in the cannabis sector.

Bioxyne’s CEO, Sam Watson, said: “This award demonstrates BLS commitment to the responsible manufacture of alternative medicines, which can provide solutions to mental health disorders resistant to current treatments. BLS aims to be the leading supplier of Psilocybin and MDMA for clinical trials and authorised prescribers, focusing on partnerships with veteran groups, universities (in Australia and abroad), and trial sponsors. There is a significant market for these products worldwide which have the potential to plug the gap in existing treatment options.”

Bioxyne faces some challenges and uncertainties in the medical cannabis industry, and seeks to overcome them with innovation and collaboration

Bioxyne faces some challenges and uncertainties in the medical cannabis industry, and seeks to overcome them with innovation and collaboration. The company has to comply with the state and federal laws, regulations, and guidelines, which are still evolving and vary across different jurisdictions. The company also has to deal with the taxation, banking, and enforcement issues, which pose potential legal and financial risks and liabilities for the company.

Bioxyne is also aware of the compatibility and suitability of the medical cannabis industry with the state’s vision, goals, and plans, especially regarding the economic development, the historic preservation, and the tourism promotion of the state. The company has to ensure that its products and operations do not adversely affect the public health, safety, and welfare of the state, and that they protect the state’s character, values, and quality of life.

Bioxyne is confident that it can overcome these challenges and uncertainties with its innovation and collaboration. The company is constantly improving and enhancing its products and processes, using the latest technology and research. The company is also working closely with the government, the industry, the academia, and the community, to ensure that its products and operations are aligned with the best interests and expectations of the stakeholders.

Bioxyne’s subsidiary, Breathe Life Sciences, has secured a GMP license from the TGA to manufacture medical cannabis products in Australia. The company is committed to the responsible and ethical manufacture of alternative medicines, and aims to provide solutions for mental health disorders. The company faces some challenges and uncertainties in the medical cannabis industry, and seeks to overcome them with innovation and collaboration.